Rhumbline Advisers Lowers Stock Holdings in Eyepoint Pharmaceuticals, Inc. $EYPT

Rhumbline Advisers cut its holdings in Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) by 3.2% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 86,732 shares of the company’s stock after selling 2,828 shares during the period. Rhumbline Advisers owned about 0.13% of Eyepoint Pharmaceuticals worth $470,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Bank of America Corp DE increased its position in Eyepoint Pharmaceuticals by 28.8% during the 4th quarter. Bank of America Corp DE now owns 648,030 shares of the company’s stock worth $4,828,000 after purchasing an additional 145,065 shares during the period. Invesco Ltd. increased its holdings in Eyepoint Pharmaceuticals by 174.3% in the 1st quarter. Invesco Ltd. now owns 42,948 shares of the company’s stock valued at $233,000 after purchasing an additional 27,291 shares in the last quarter. ProShare Advisors LLC increased its holdings in Eyepoint Pharmaceuticals by 70.7% in the 4th quarter. ProShare Advisors LLC now owns 21,679 shares of the company’s stock valued at $162,000 after purchasing an additional 8,981 shares in the last quarter. American Century Companies Inc. bought a new position in shares of Eyepoint Pharmaceuticals during the first quarter worth about $232,000. Finally, Millennium Management LLC bought a new position in Eyepoint Pharmaceuticals in the fourth quarter worth about $3,324,000. 99.41% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on EYPT. HC Wainwright raised their price objective on shares of Eyepoint Pharmaceuticals from $22.00 to $23.00 and gave the company a “buy” rating in a research note on Wednesday, August 6th. Royal Bank Of Canada assumed coverage on shares of Eyepoint Pharmaceuticals in a report on Tuesday, June 17th. They set an “outperform” rating and a $28.00 price objective on the stock. Finally, Chardan Capital reiterated a “buy” rating and set a $27.00 target price on shares of Eyepoint Pharmaceuticals in a research report on Thursday, August 7th. Seven investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Eyepoint Pharmaceuticals has an average rating of “Buy” and an average price target of $26.86.

Eyepoint Pharmaceuticals Stock Performance

NASDAQ EYPT opened at $13.39 on Wednesday. The business’s 50 day moving average price is $11.56 and its 200-day moving average price is $8.67. The company has a market cap of $922.93 million, a P/E ratio of -5.00 and a beta of 1.93. Eyepoint Pharmaceuticals, Inc. has a fifty-two week low of $3.91 and a fifty-two week high of $14.42.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last issued its quarterly earnings data on Wednesday, August 6th. The company reported ($0.85) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.18). The company had revenue of $5.33 million for the quarter, compared to analysts’ expectations of $6.82 million. Eyepoint Pharmaceuticals had a negative return on equity of 63.80% and a negative net margin of 337.93%. As a group, equities analysts predict that Eyepoint Pharmaceuticals, Inc. will post -2.13 EPS for the current year.

Eyepoint Pharmaceuticals Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.